|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 379.10 DKK | -0.62% |
|
+9.33% | +16.56% |
| 06:11am | Amgen says MariTide helped trial patients maintain weight loss | RE |
| 05:46am | Appetite for weight-loss deals broader than visible, Viking CEO says | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | DKK 392.29 | +2.84% | 20 | ||||||
| $1,116.33 | +4.96% | 27 | ||||||
| $212 | +3.72% | 24 | ||||||
| $244.59 | +11.14% | 27 | ||||||
| CHF 334.07 | -1.98% | 16 | ||||||
| GBX 203.79 | +6.93% | 19 | ||||||
| $113.33 | +2.54% | 27 | ||||||
| CHF 137.35 | -3.45% | 19 | ||||||
| $330.41 | +1.32% | 27 | ||||||
| $134.22 | +10.84% | 26 | ||||||
| $28.66 | +12.47% | 24 | ||||||
| €102.77 | +21.71% | 21 | ||||||
| $500.4 | +7.88% | 25 | ||||||
| $56.57 | +1.26% | 23 | ||||||
| GBX 18.84 | -0.1% | 18 | ||||||
| JP¥8,764.29 | +4.08% | 14 | ||||||
| CN¥82.86 | +29.92% | 17 | ||||||
| $490.29 | +23.1% | 24 | ||||||
| JP¥4,960.43 | -2.35% | 14 | ||||||
| Average | 959.13 | +7.20% | 22 | ||||||
| Weighted average by Cap. | 631.72 | +5.21% | 23 |
- Stock Market
- Equities
- NOVO B Stock
- Sector Novo Nordisk A/S
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition